Glazer Capital, LLC 13D and 13G filings for Revance Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-06 6:19 pm Purchase |
2025-01-30 | 13G | Revance Therapeutics, Inc. RVNC |
Glazer Capital, LLC | 7,210,121 6.870% |
7,210,121 (New Position) |
Filing |